Show simple item record

Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality

dc.contributor.authorRychter, Anna
dc.contributor.authorMiniszewska, Joanna
dc.contributor.authorGóra-Tybor, Joanna
dc.date.accessioned2023-10-18T11:08:09Z
dc.date.available2023-10-18T11:08:09Z
dc.date.issued2023
dc.identifier.citationRychter, A., Miniszewska, J. & Góra-Tybor, J. Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality. BioPsychoSocial Med 17, 1 (2023). https://doi.org/10.1186/s13030-023-00261-wpl_PL
dc.identifier.issn1751-0759
dc.identifier.urihttp://hdl.handle.net/11089/48100
dc.description.abstractBackground The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence. Methods The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib. Results 39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (p = 0.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (p = 0.020). Conclusion The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence.pl_PL
dc.language.isoenpl_PL
dc.publisherSpringer Naturepl_PL
dc.relation.ispartofseriesBioPsychoSocial Medicine;17:1
dc.rightsUznanie autorstwa 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectPersonality traitspl_PL
dc.subjectType A personalitypl_PL
dc.subjectType D personalitypl_PL
dc.subjectChronic myeloid leukemiapl_PL
dc.subjectAdherencepl_PL
dc.titlePersonality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personalitypl_PL
dc.typeArticlepl_PL
dc.page.number7pl_PL
dc.contributor.authorAffiliationDepartment of Haematology, Medical University of Lodz, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Health Psychology, Institute of Psychology, Lodz University, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Haematology, Medical University of Lodz, Lodz, Polandpl_PL
dc.referencesNoens L, van Lierde MA, de Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11. https://doi.org/10.1182/blood-2008-12-196543.pl_PL
dc.referencesKimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27:3445–51. https://doi.org/10.1200/JCO.2008.19.2419.pl_PL
dc.referencesIbrahim A, Eliasson L, Apperley J, Milojkovic D, Bua M, Szydlo R, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for CML patients on long term therapy. Blood. 2011;117:3733–6. https://doi.org/10.1182/blood-2010-10-309807.pl_PL
dc.referencesEfficace F, Baccarani M, Rosti G, Cottone F, Castagnetti F, Breccia M, et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br J Cancer. 2012;107:904–9. https://doi.org/10.1038/bjc.2012.348.pl_PL
dc.referencesJabbour E, Kantarjian H, Eliasson L, Cornelison M, Marinet D. Patent adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol. 2012;87:687–91. https://doi.org/10.1002/ajh.23180.pl_PL
dc.referencesvan Wijk B, Klungel O, Heerdink E, de Boer A. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens. 2004;22:1831–7. https://doi.org/10.1097/00004872-200409000-00029.pl_PL
dc.referencesRychter A, Jerzmanowski P, Hołub A, Specht-Szwoch Z, Kalinowska V, Tęgowska U, et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol. 2017;34:104. https://doi.org/10.1007/s12032-017-0958-6.pl_PL
dc.referencesBruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med. 2010;33:219–27. https://doi.org/10.1007/s10865-010-9247-y.pl_PL
dc.referencesAxelsson M, Brink E, Lötvall J. A personality and gender perspective on adherence and health-related quality of life in people with asthma and/or allergic rhinitis. J Am Assoc Nurse Pract. 2014;26:32–9. https://doi.org/10.1002/2327-6924.12069.pl_PL
dc.referencesJerant A, Chapman B, Duberstein P, Robbins J, Franks P. Personality and medication non-adherence among older adults enrolled in a six-year trial. Br J Health Psychol. 2011;16:151–69. https://doi.org/10.1348/135910710X524219.pl_PL
dc.referencesSkinner TC, Bruce DG, Davis TME, Davis WA. Research: educational and psychological issues personality traits, self-care behaviours and glycaemic control in type 2 diabetes: the Fremantle Diabetes Study Phase II. Diabet Med. 2014;31:487–92. https://doi.org/10.1111/dme.12339.pl_PL
dc.referencesFriedman M, Rosenman RH. Type A behaviour and your heart. New York: Knopf; 1974.pl_PL
dc.referencesTorgersen S, Vollrath M. Personality types, personality traits and risky health, behaviours. In: Vollrath ME, editor. Handbook of personality and health. Chichester: Wiley; 2006. p. 215–33.pl_PL
dc.referencesFriedman M, Rosenman RH. Association of specific overt behavior pattern with blond and cardiovascular findings. JAMA. 1959;169:1286–96.pl_PL
dc.referencesWrześniewski K. Styl życia a zdrowie. Wzór zachowania A. Warszawa: PAN; 1993.pl_PL
dc.referencesZaleska T, Tylka J. Typ a zachowania a choroba niedokrwienna serca. Kard Pol. 1992;34:313–8.pl_PL
dc.referencesRagland DR, Brand RJ, Fox BH. Type A/B behavior and cancer mortality: the confounding/mediating effect of covariates. Psychooncology. 1992;1:25–33. https://doi.org/10.1002/pon.2960010105.pl_PL
dc.referencesChauvet-Gélinier J-C, Mosca-Boidron A-L, Lemogne C, et al. Type a competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes. Diabetes Metab. 2019;45(6):582–5. https://doi.org/10.1016/j.diabet.2018.11.005.pl_PL
dc.referencesMarcinkowska-Bachlińska M, Małecka-Panas E. The role of the type A behaviour in the pathogenesis of gastroesophageal reflux disease. Przegl Gastroenterol. 2006;1:2: 98–104.pl_PL
dc.referencesChesney MA, Hecker MH, Black GW. Coronary-prone competents of type A behavior in the WCGS: a new methology. Houston BK, Snyder CR (editor). Type A behavior pattern: research, theory and interwention. New York: Wiley; 1988. p. 26–35.pl_PL
dc.referencesFriedman M, Powell LH. The diagnosis and quantitative assessment of type A behavior: introduction and description of the videotyped structured interview. Integr Psychiatry. 1984;2:121–9.pl_PL
dc.referencesBarefoot JC, Peterson BL, Dahlstrom WG. Hostility patterns and health implications: correlates of Cook-Medley hostility scale scores in a national survey. Health Psychol. 1991;10:18–24. https://doi.org/10.1037//0278-6133.10.1.18.pl_PL
dc.referencesBroström A, Strömberg A, Martensson J, Ulander M, Harder L, Svanborg E. Association of type D personality to perceived side effects and adherence in CPAP-treated patients with OSAS. J Sleep Res. 2007;16:439–47. https://doi.org/10.1111/j.1365-2869.2007.00620.x.pl_PL
dc.referencesWu JR, Song EK, Moser DK, Type D. Personality, self-efficacy, and medication adherence in patients with heart failure-A mediation analysis. Heart Lung. 2015;44:276–81. https://doi.org/10.1016/j.hrtlng.2015.03.006.pl_PL
dc.referencesWilliams L, O’Connorb RC, Grubbc N, O’Carroll R. Type D personality predicts poor medication adherence in myocardial infarction patients. Psychol Health. 2011;26:703–12. https://doi.org/10.1080/08870446.2010.488265.pl_PL
dc.referencesCrawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: a systematic review and meta-analysis. J Psychosom Res. 2016;90:10–32. https://doi.org/10.1016/j.jpsychores.2016.09.003.pl_PL
dc.referencesCosta PT, McCrae RR Jr. Revised NEO personality inventory manual. Odessa: Psychological Assessment Resources, Inc; 1992.pl_PL
dc.referencesZawadzki B, Strelau J, Szczepaniak P, Śliwińska M. Inwentarz osobowości NEO-FFI Costy i McCrae. Warszawa: Pracownia Testów Psychologicznych PTP; 1998.pl_PL
dc.referencesFramingham. Heart Study - www.framinghamheartstudy.org.pl_PL
dc.referencesDawber TR, Kannel WB, Revotskie N, Stokes JI, Kagan A, Gordon T. Some factors associated with the development of coronary heart disease. Six years’ follow-up experience in the Framingham study. Am J Public Health. 1959;49:1349–56. https://doi.org/10.2105/ajph.49.10.1349.pl_PL
dc.referencesJuczyński Z. Narzędzia pomiaru w promocji i psychologii zdrowia. Warszawa: Pracownia Testów Psychologicznych Polskiego Towarzystwa Psychologicznego; 2001.pl_PL
dc.referencesDenollet J. DS14: standard assessment of negative affectivity, social inhibition and type D personality. Psych Med. 2005;67:89–97. https://doi.org/10.1097/01.psy.0000149256.81953.49.pl_PL
dc.referencesJuczyński Z, Ogińska-Bulik N. Narzędzia pomiaru stresu i radzenia sobie ze stresem. Warszawa: Pracownia Testów Psychologicznych PTP; 2009.pl_PL
dc.referencesMiličić D, Brajković L, Maček JL, Andrić A, Ardalić Ž, Buratović T, et al. Type a personality, stress, anxiety and health locus of control in patients with acute myocardial infarction. Psychiatr Danub. 2016;28:409–14.pl_PL
dc.referencesLi X, Zhang S, Xu H, Tang X, Zhou H, Yuan J, et al. Type D personality predicts poor medication adherence in Chinese patients with type 2 diabetes mellitus: a six-month follow-up study. PLoS One. 2016;11:e0146892. https://doi.org/10.1371/journal.pone.0146892.pl_PL
dc.referencesDe Fruyt F, Denollet J. Type D personality: a five factor model perspective. Psych Health. 2002;5:671–83. https://doi.org/10.1080/08870440290025858.pl_PL
dc.referencesWouters H, Amin D, Taxis K, Heerdink ER, Egberts A, Gardarsdottir H. Associations between personality traits and adherence to antidepressants assessed through self-report, electronic monitoring, and pharmacy dispensing data: a pilot study. J Clin Psychopharmacol. 2016;36:465–71. https://doi.org/10.1097/JCP.0000000000000541.pl_PL
dc.referencesCohen NL, Ross EC, Bagby RM, Farvolden P, Kennedy SH. The 5-factor model of personality and antidepressant medication compliance. Can J Psychiatry. 2004;49:106–13. https://doi.org/10.1177/070674370404900205.pl_PL
dc.referencesAxelsson M, Brink E, Lundgren J, Lötvall J. The influence of personality traits on reported adherence to medication in individuals with chronic disease: an epidemiological study in West Sweden. PLoS One. 2011;6:e18241. https://doi.org/10.1371/journal.pone.001824.pl_PL
dc.referencesAdachi T, Tsunekawa Y, Tanimura D. Association between the big five personality traits and medication adherence in patients with cardiovascular disease: a cross-sectional study. PLoS One. 2022;17:e0278534. https://doi.org/10.1371/journal.pone.0278534.pl_PL
dc.referencesToelle BG, Marks GB, Dunn SM. Psychological andmedical characteristics associated with non-adherence to prescribed dailyinhaled corticosteroid. J Pers Med. 2020;10:126. https://doi.org/10.3390/jpm10030126.pl_PL
dc.referencesFeingold A. Gender differences in personality - a meta-analysis. Psychol Bull. 1994;116:429–56. https://doi.org/10.1037/0033-2909.116.3.429.pl_PL
dc.identifier.doi10.1186/s13030-023-00261-w
dc.disciplinepsychologiapl_PL


Files in this item

Thumbnail
Name:
s13030-023-00261-w (1).pdf
Size:
990.0Kb
Format:
PDF
View/Open
Thumbnail
Name:
license_rdf
Size:
908bytes
Format:
application/rdf+xml
View/Open

This item appears in the following Collection(s)

Show simple item record

Uznanie autorstwa 4.0 Międzynarodowe
Except where otherwise noted, this item's license is described as Uznanie autorstwa 4.0 Międzynarodowe